ClinicalTrials.gg

Colorectal Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 6,552 studies for Colorectal Neoplasms across more than 10 countries. 1,664 are recruiting or about to start. 4,878 of them are mainly about Colorectal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 8 narrower conditions too, such as Colonic Neoplasms: 10,059 studies, 2,667 open.

ClinicalTrials.gov finds 10,400 studies for Colorectal Neoplasms. How that becomes 6,545 here

This page counts the studies the registry files under Colorectal Neoplasms, and those it files under no condition that list Colorectal Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 10,400Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3,276Filed under a narrower condition, counted on its own pageRectal Neoplasms 1,617 · Colonic Neoplasms 1,241 · Anus Neoplasms 216 · Colorectal Neoplasms, Hereditary Nonpolyposis 95 · Adenomatous Polyposis Coli 67 · Sigmoid Neoplasms 5 · 1 more
  3. −99List Colorectal Neoplasms as a condition, but the registry did not file them under itMost often written as “Colorectal Cancer Metastatic” (24), “Colorectal Cancer Screening” (9), and “Microsatellite Stable Colorectal Cancer” (8). The registry filed them under other conditions only, most often Carcinoma, Non-Small-Cell Lung (22) and Neoplasms (18).
  4. −485Match it another way231 name it in the title, 30 in a keyword, and 224 by a synonym or other text the search reads.
  5. 6,540Counted here and found by its search402 of them list Colorectal Neoplasms in their own words; the registry filed them under no condition.
  6. +5
    Counted here, but its search does not find them
  7. 6,545The count on this page

Status

Completed
2,857
Recruiting
1,178
Status unknown
878
Terminated
536
Not yet recruiting
430
Active, not recruiting
402

Phase

Phase 2
2,058
Phase 1
1,308
Phase 3
548
Phase 4
113
Early Phase 1
61

Where

United States
2,341
China
1,136
France
582
Spain
463
Italy
429
United Kingdom
388

Who develops what

Add Colorectal Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 212 programs from 143 companies, 121 with this as their studies’ main aim; 30 with a live phase 3 study; 32 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Sino Biopharmaceutical and BioNTech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BevacizumabRecent, repeated
Evidence
  • NCT07895355 · RemeGen Co., Ltd. · Phase 2 · live · comparator · “Telisotuzumab adizutecan plus Bevacizumab” · registered Oct 2026
  • NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2026
  • NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Bevacizumab injection” · registered Aug 2026
  • NCT07775287 · Genmab · Phase 3 · live · comparator · “Bevacizumab” · registered Aug 2026
  • NCT07750041 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “bevacizumab + FOLFOXIRI” · registered Aug 2026
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others3844 studies
FluorouracilRecent, repeated
Evidence
  • NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Fluorouracil” · registered Sep 2026
  • NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “5-fluorouracil” · registered Sep 2026
  • NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Fluorouracil” · registered Aug 2026
  • NCT07775287 · Genmab · Phase 3 · live · background · “5-FU” · registered Aug 2026
  • NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “5-Fluorouracil / Leucovorin Calcium” · registered Jul 2026
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed1520 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
  • NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
  • NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Aug 2026
  • NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Oxaliplatin injection” · registered Aug 2026
  • NCT07775287 · Genmab · Phase 3 · live · background · “Oxaliplatin” · registered Aug 2026
Sanofi35% of its industry studies1418 studies
LeucovorinRecent, repeated
Evidence
  • NCT07844187 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Calcium folinate (leucovorin calcium)” · registered Sep 2026
  • NCT07814417 · Eli Lilly and Company · Phase 2 · live · background · “Leucovorin/levofolinate calcium” · registered Sep 2026
  • NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Leucovorin” · registered Aug 2026
  • NCT07775287 · Genmab · Phase 3 · live · background · “Leucovorin (Calcium Folinate)” · registered Aug 2026
  • NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “5-Fluorouracil / Leucovorin Calcium” · registered Jul 2026
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed1418 studies
FOLFIRI RegimenRecent, repeated
Evidence
  • NCT07790510 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · background · “FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU)” · registered Aug 2026
  • NCT07702032 · Genmab · Phase 3 · live · background · “FOLFIRI” · registered Jul 2026
  • NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFIRI” · registered Jan 2026
  • NCT07391566 · Luye Pharma Group Ltd. · Phase 2 · live · background · “FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)” · registered Dec 2025
  • NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFIRI” · registered Oct 2025
—1313 studies
CetuximabRecent, repeated
Evidence
  • NCT07939815 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Nov 2026
  • NCT07775287 · Genmab · Phase 3 · live · comparator · “Cetuximab” · registered Aug 2026
  • NCT07702032 · Genmab · Phase 3 · live · comparator · “Cetuximab” · registered Jul 2026
  • NCT07659795 · Verastem, Inc. · Phase 2 · live · background · “cetuximab” · registered Jun 2026
  • NCT07595276 · Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 3 · live · comparator · “Erbitux®” · registered May 2026
Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004)1218 studies
trifluridine tipiracil drug combinationRecent, repeated
Evidence
  • NCT07913360 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Trifluridine and Tipiracil” · registered Oct 2026
  • NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “TAS-102” · registered Jul 2026
  • NCT07549412 · Merck KGaA, Darmstadt, Germany · Phase 3 · live · comparator · “Trifluridine/Tipiracil (FTD-TPI)” · registered Apr 2026
  • NCT06607458 · Delcath Systems Inc. · Phase 2 · live · comparator · “Trifluridine-tipiracil plus Bevacizumab Alone” · registered Sep 2024
  • NCT06039202 · Holy Stone Healthcare Co., Ltd · Phase 2 · background · “TAS-102” · registered Sep 2023
Otsuka Holdings Co., Ltd.52% of its industry studies1010 studies
FOLFIRI-Ziv-aflibercept RegimenRecent, repeated
Evidence
  • NCT07702032 · Genmab · Phase 3 · live · background · “FOLFIRI” · registered Jul 2026
  • NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFIRI” · registered Jan 2026
  • NCT07391566 · Luye Pharma Group Ltd. · Phase 2 · live · background · “FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)” · registered Dec 2025
  • NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFIRI” · registered Oct 2025
  • NCT06936527 · Fosun Pharma · Phase 2 · live · comparator · “Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI” · registered Apr 2025
—99 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07255664 · CuraCell TX AB · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06699836 · CytoDyn, Inc. · Phase 2 · live · background · “200 mg pembrolizumab” · registered Nov 2024
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)88 studies
IrinotecanRecent, repeated
Evidence
  • NCT07775287 · Genmab · Phase 3 · live · background · “Irinotecan” · registered Aug 2026
  • NCT07474727 · Multitude Therapeutics Inc. · Phase 2 · live · background · “Irinotecan” · registered Mar 2026
  • NCT07134205 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Irinotecan” · registered Aug 2025
  • NCT06750094 · Johnson & Johnson · Phase 3 · live · background · “Irinotecan” · registered Dec 2024
  • NCT06662786 · Johnson & Johnson · Phase 3 · live · background · “Irinotecan Hydrochloride” · registered Oct 2024
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)812 studies
CapecitabineRecent, repeated
Evidence
  • NCT07805551 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Capecitabine” · registered Aug 2026
  • NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Capecitabine tablets” · registered Aug 2026
  • NCT07737600 · lepu biopharma co ltd · Phase 2 · live · background · “Capecitabine” · registered Jul 2026
  • NCT07412613 · Akeso · Phase 3 · live · comparator · “Capecitabine” · registered Feb 2026
  • NCT07025239 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jun 2025
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized810 studies
fruquintinibRecent, repeated
Evidence
  • NCT07913360 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Fruquintinib” · registered Oct 2026
  • NCT07791758 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Fruquintinib Capsules” · registered Aug 2026
  • NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Fruquintinib” · registered Jul 2026
  • NCT07621159 · Huadong Medicine Co., Ltd. · Phase 2 · live · background · “Fruquintinib” · registered May 2026
  • NCT07235293 · Kahr Bio Australia Pty Ltd · Phase 2 · live · comparator · “Fruquintinib” · registered Nov 2025
HUTCHMED85% of its industry studiesUS: Takeda (FDA 2023)EU: Takeda (EMA 2024)88 studies
Folfox protocolRecent, repeated
Evidence
  • NCT07323576 · Hoffmann-La Roche · Phase 2 · background · “FOLFOX” · registered Jan 2026
  • NCT07284849 · Incyte Corporation · Phase 3 · live · background · “FOLFOX” · registered Dec 2025
  • NCT07221357 · Bristol-Myers Squibb · Phase 3 · live · background · “FOLFOX” · registered Oct 2025
  • NCT06936527 · Fosun Pharma · Phase 2 · live · comparator · “Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI” · registered Apr 2025
  • NCT06598007 · Crossignal Therapeutics, Inc. · Phase 2 · live · background · “FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)” · registered Sep 2024
Hoffmann-La Roche20% of its industry studies77 studies
regorafenibRecent, repeated
Evidence
  • NCT07730489 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Regorafenib” · registered Jul 2026
  • NCT07134205 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Regorafenib” · registered Aug 2025
  • NCT06089330 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Regorafenib (Stivarga)” · registered Oct 2023
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Regorafenib” · registered Aug 2023
  • NCT05600309 · Merck & Co., Inc · Phase 3 · comparator · “regorafenib” · registered Oct 2022
Bayer80% of its industry studiesUS: Bayer (FDA 2012)EU: Bayer (EMA 2013)78 studies
Modified FOLFOX6 RegimenRecent, repeated
Evidence
  • NCT07790510 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · background · “mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU)” · registered Aug 2026
  • NCT07702032 · Genmab · Phase 3 · live · background · “mFOLFOX6” · registered Jul 2026
  • NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “mFOLFOX6 regimen” · registered May 2024
  • NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “mFOLFOX6” · registered Mar 2024
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “mFOLFOX-6” · registered May 2023
—66 studies
NivolumabRecent, repeated
Evidence
  • NCT07527858 · Gilead Sciences · Phase 2 · live · background · “Nivolumab” · registered Apr 2026
  • NCT06948448 · Ono Pharmaceutical Co. Ltd · Phase 2 · live · background · “Opdivo®” · registered Apr 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Nivolumab” · registered May 2023
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)55 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
  • NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
Eli Lilly and Company16% of its industry studies44 studies
GemcitabineRecent, repeated
Evidence
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “gemcitabine” · registered May 2024
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Gemcitabine” · registered Jul 2022
  • NCT05116891 · Cantargia AB · Phase 2 · background · “G/C” · registered Oct 2021
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed44 studies
CisplatinRecent, repeated
Evidence
  • NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
  • NCT06428409 · Merck & Co., Inc · Phase 2 · live · background · “Cisplatin” · registered May 2024
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Gemcitabine Combined With Cisplatin” · registered Jul 2022
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
  • NCT05116891 · Cantargia AB · Phase 2 · background · “G/C” · registered Oct 2021
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed44 studies
atezolizumabRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
  • NCT05733611 · Replimune, Inc. · Phase 2 · background · “atezolizumab” · registered Feb 2023
  • NCT05456165 · Gritstone bio, Inc. · Phase 2 · background · “Atezolizumab” · registered Jul 2022
  • NCT05425940 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered Jun 2022
  • NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Atezolizumab” · registered Nov 2021
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)45 studies
IpilimumabRecent, repeated
Evidence
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
  • NCT05456165 · Gritstone bio, Inc. · Phase 2 · background · “Ipilimumab” · registered Jul 2022
  • NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Ipilimumab” · registered Nov 2021
  • NCT03126110 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Apr 2017
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)44 studies
PaclitaxelRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Paclitaxel” · registered Jul 2022
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
  • NCT04083599 · Genmab · Phase 2 · live · background · “Paclitaxel” · registered Sep 2019
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed33 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06445062 · Revolution Medicines, Inc. · Phase 2 · live · background · “nab-paclitaxel” · registered May 2024
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Abraxane” · registered Jul 2022
  • NCT04083599 · Genmab · Phase 2 · live · background · “Nab paclitaxel” · registered Sep 2019
  • NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Nab paclitaxel.” · registered Sep 2018
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)33 studies
LevoleucovorinRecent, repeated
Evidence
  • NCT07676162 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab” · registered Jun 2026
  • NCT06750094 · Johnson & Johnson · Phase 3 · live · background · “Leucovorin calcium/Levoleucovorin” · registered Dec 2024
  • NCT06662786 · Johnson & Johnson · Phase 3 · live · background · “Leucovorin calcium/Levoleucovorin” · registered Oct 2024
  • NCT05253651 · Pfizer · Phase 3 · live · background · “levoleucovorin” · registered Feb 2022
  • NCT04456699 · Merck & Co., Inc · Phase 3 · comparator · “Leucovorin/ levoleucovorin” · registered Jul 2020
Aurobindo Pharma100% of its industry studies34 studies
tislelizumabRecent, repeated
Evidence
  • NCT07468071 · Novartis · Phase 2 · live · background · “tislelizumab” · registered Mar 2026
  • NCT07244705 · Anbogen Therapeutics, Inc. · Phase 2 · live · background · “Tislelizumab” · registered Nov 2025
  • NCT05651022 · Indaptus Therapeutics, Inc · Phase 2 · live · background · “Tislelizumab” · registered Nov 2022
  • NCT04952753 · Novartis · Phase 2 · background · “Tislelizumab” · registered Jun 2021
  • NCT04699188 · Novartis · Phase 2 · live · background · “tislelizumab” · registered Jan 2021
BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023)33 studies
DocetaxelRecent, repeated
Evidence
  • NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Docetaxel” · registered Mar 2024
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT05116891 · Cantargia AB · Phase 2 · background · “DTX” · registered Oct 2021
  • NCT04256707 · Karyopharm Therapeutics Inc · Phase 2 · background · “Docetaxel” · registered Feb 2020
  • NCT04165031 · Eli Lilly and Company · Phase 2 · comparator · “Docetaxel” · registered Nov 2019
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized22 studies
PemetrexedRecent, repeated
Evidence
  • NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)” · registered Feb 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT04083599 · Genmab · Phase 2 · live · background · “Pemetrexed” · registered Sep 2019
  • NCT03267316 · Cantargia AB · Phase 2 · background · “Pemetrexed” · registered Aug 2017
  • NCT03085914 · Incyte Corporation · Phase 2 · background · “Pemetrexed” · registered Feb 2017
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized22 studies
TrastuzumabRecent, repeated
Evidence
  • NCT06589830 · Teligene US · Phase 2 · live · background · “Trastuzumab” · registered Sep 2024
  • NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab” · registered Mar 2024
  • NCT05091528 · Silverback Therapeutics · Phase 2 · background · “trastuzumab” · registered Oct 2021
  • NCT04579380 · Pfizer · Phase 2 · live · background · “trastuzumab” · registered Oct 2020
  • NCT04464967 · NKGen Biotech, Inc. · Phase 2 · background · “Trastuzumab” · registered Jul 2020
Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others22 studies
trastuzumab deruxtecanRecent, repeated
Evidence
  • NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab deruxtecan” · registered Mar 2024
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “trastuzumab deruxtecan (T-DXd)” · registered Mar 2023
  • NCT05091528 · Silverback Therapeutics · Phase 2 · background · “trastuzumab deruxtecan” · registered Oct 2021
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “T- Dxd” · registered Oct 2020
Daiichi Sankyo53% of its industry studiesUS: Daiichi Sankyo (FDA 2019)EU: Daiichi Sankyo (EMA 2021)22 studies
PrednisoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Prednisone” · registered May 2026
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Prednisone/ prednisolone” · registered Jul 2022
Johnson & Johnson11% of its industry studies22 studies
trametinibRecent, repeated
Evidence
  • NCT07468071 · Novartis · Phase 2 · live · background · “trametinib” · registered Mar 2026
  • NCT05358249 · Novartis · Phase 2 · background · “trametinib” · registered Apr 2022
  • NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014)23 studies
FluoropyrimidineRecent, repeated
Evidence
  • NCT05609370 · BeOne Medicines · Phase 2 · live · background · “Fluoropyrimidine (FP)” · registered Oct 2022
  • NCT05141721 · Seattle Project Corporation · Phase 3 · live · background · “Fluoropyrimidine plus leucovorin” · registered Nov 2021
Hoffmann-La Roche50% of its industry studies22 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07222800 · Pfizer · Phase 3 · live · background · “Chemotherapy” · registered Oct 2025
  • NCT05731947 · Syndax Pharmaceuticals · Phase 2 · comparator · “Chemotherapy” · registered Feb 2023
  • NCT04868877 · Genmab · Phase 2 · background · “Chemotherapy” · registered Apr 2021
  • NCT02327078 · Incyte Corporation · Phase 2 · background · “Chemotherapy” · registered Dec 2014
  • NCT02202928 · Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 2 · background · “Chemotherapy” · registered Jul 2014
—22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07255664 · CuraCell TX AB · Phase 2 · live · background · “Cyclophosphamid” · registered Nov 2025
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT03563157 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered May 2018
  • NCT03169777 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered May 2017
  • NCT03085914 · Incyte Corporation · Phase 2 · background · “Cyclophosphamide” · registered Feb 2017
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

38 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
becotatug☆ Track1 live phase-3 study: NCT07134205CSPC Pharmaceutical Group Limited
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102☆ Track1 live phase-3 study: NCT07483684Sino Biopharmaceutical Limited
trifluridine tipiracil drug combination☆ Track1 live phase-3 study: NCT07483684Sino Biopharmaceutical Limited
anbenitamab repodatecan☆ Track1 live phase-3 study: NCT07384377CSPC Pharmaceutical Group Limited
trastuzumab brengitecan☆ Track1 live phase-3 study: NCT07730489Sichuan Biokin Pharmaceutical Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 212 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (32)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Tetrodotoxin · Dogwood Therapeutics Inc. · Phase 2 registry mapping onlyNCT06848348 Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain — primary endpoint: NRS Pain · 240 enrolled
  • Dec 2026 est.TH9619 · One-carbon Therapeutics AB · Phase 2 main aimNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors — primary endpoint: Frequency of treatment-emergent adverse events (TEAEs) · 43 enrolled
  • Dec 2026 est.SSGJ-706, xelox · 3SBio Inc. · Phase 2 main aimNCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers — primary endpoint: Incidence and severity of Adverse Events · 300 enrolled

29 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Colorectal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 129 open · Antimetabolites 63 open · Tyrosine kinase inhibitors (TKIs) 57 open · Angiogenesis inhibitors 40 open · Antibody-drug conjugates (ADCs) 12 open

Coming up

576studies finish main data collection within a year19 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger. 48 (4%) take children under 18. 3 (<1%) are for women only and 1 (<1%) for men only; 123 (10%) take healthy volunteers.

Recruiting studies that take each age, of 1,178
AgeWomenMen
1034 (3%)34 (3%)
181,051 (89%)1,048 (89%)
301,091 (93%)1,088 (92%)
401,112 (94%)1,110 (94%)
501,150 (98%)1,148 (97%)
651,150 (98%)1,148 (97%)
751,086 (92%)1,084 (92%)
85834 (71%)831 (71%)

Across all 6,552 studies, recruiting or not: 21% stop at 75 or younger and 3% at 65; 5% take children; 1% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Colorectal Neoplasms studies take

Of 618 phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 148 mo31–70 · 435 studies47 mo31–66 · 269 studies49 mo31–74 · 166 studies
Phase 1/259 mo36–87 · 260 studies59 mo39–82 · 158 studies57 mo36–106 · 102 studies
Phase 249 mo31–75 · 618 studies34 mo26–72 · 120 studies55 mo33–75 · 498 studies
Phase 2/356 mo44–105 · 36 studies——
Phase 350 mo35–79 · 175 studies43 mo26–54 · 69 studies65 mo42–116 · 106 studies
Phase 449 mo29–57 · 38 studies——
Interventional, no phase31 mo14–60 · 957 studies16 mo9–37 · 57 studies32 mo15–61 · 900 studies
Observational52 mo27–104 · 647 studies45 mo30–60 · 117 studies56 mo27–132 · 530 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered49

Show 44 more

Studies

Recruiting first, then most recently updated. Showing 50 of 6,552. Browse all 6,552 → or search them.